Search clinical trials for: ABL001 Nilotinib

Total 3233 results

Sound Biopharmaceuticals Ltd.

Recruiting

Study in Patients With Advanced Solid Malignancies to Evaluate the Safety of FTL001

Solid Tumor

China
Abion Inc

Recruiting

To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation

Advanced Solid Tumors

Korea, Republic of, Taiwan, United States
Abcuro, Inc.

Recruiting

ABC008 in Subjects With T-cell Large Granular Lymphocytic Leukemia (T-LGLL)

T-cell Large Granular Lymphocytic Leukemia

United States
Abcuro, Inc.

Active, not recruiting

A Phase 1 Study of ABC008 in Ascending (Single Ascending Dose/Multiple Ascending Dose) Study in Patients With (IBM)

Inclusion Body Myositis

Australia
Coegin Pharma AB
Bispebjerg Hospital; Studies&Me

Active, not recruiting

Phase I/IIa Trial to Evaluate AVX001 Gel in Doses of 1% or 3% Compared With Vehicle Over Four Weeks of Field-directed Treatment Period in Adult Subjects With AK (COAKS)

Actinic Keratoses

Denmark
AJNA Australia Pty Ltd

Not yet recruiting

A SAD, MAD and Food Effect Study to Evaluate the Safety, Tolerability, PK, and PD of AJA001 in Healthy Subjects

Healthy Volunteers
AriBio Co., Ltd.

Recruiting

Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)

Alzheimer Disease

United States, Korea, Republic of
Avotres Inc.

Active, not recruiting

Safety, Tolerability and Potential Efficacy of AVT001 in Patients With Type 1 Diabetes

Type 1 Diabetes Mellitus

United States
AriBio Co., Ltd.

Completed

Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease

Mild to Moderate Alzheimer's Disease

United States
AB Science

Completed

Masitinib in Relapse or Refractory Multiple Myeloma With t(4/14) Translocation Expressing or Not FGFR3

Multiple Myeloma

France
ObsEva SA

Terminated

A Phase 2 Study of OBE001 Versus Placebo in the Delay of Preterm Birth (TERM)

Preterm Labor

Poland, United Kingdom, Spain, Switzerland, Belgium, Germany
Abbell AB

Completed

Clinical Trial of Topical ABL01 Treatment of Onychomycosis

Onychomycosis of Toenail

Sweden
Georgetown University

Unknown

Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease (PD Nilotinib)

Parkinson Disease | Parkinsons Disease With Dementia

United States
Norgine

Completed

Safety, Tolerability, Pharmacodynamic and Pharmacokinetics of a Single Rectal Application of 10 mg NRL001 in Elderly Subjects

Fecal Incontinence

United Kingdom
Pfizer

Terminated

Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds (AEGIS)

Invasive Fungal Infections

Israel, Germany, United States, Belgium
Norgine

Completed

Effect of 7 Days of Dosing With a 10 mg Rectal Suppository of NRL001in Patients With Faecal Incontinence

Fecal Incontinence

United Kingdom
Pfizer

Completed

An Open-label Study of APX001 for Treatment of Patients With Candidemia/Invasive Candidiasis Caused by Candida Auris (APEX)

Candidemia | Candida Infection | Invasive Candidiases

South Africa
AiViva BioPharma, Inc.

Withdrawn

A Safety and Efficacy Study to Evaluate Rosacea

Papulopustular Rosacea

United States
AB Science

Completed

Efficacy of AB1010 in Patients With Systemic Indolent Mastocytosis

Mastocytosis
Norgine

Completed

Safety, Tolerability, Pharmacodynamic and Pharmacokinetics of 7.5, 10, 12.5 or 15 mg NRL001 in a 2 g Suppository for 14 Days

Fecal Incontinence

United Kingdom
AmDerma

Completed

Study Comparing AM001 Cream to Vehicle in the Treatment of Plaque Psoriasis

Skin Diseases | Skin Diseases, Papulosquamous | Plaque Psoriasis

United States
KeifeRx, LLC
Worldwide Clinical Trials; Life Molecular Imaging GmbH; Sun Pharmaceuticals Industries...

Not yet recruiting

Evaluating the Efficacy and Safety of Nilotinib BE in Subjects With Early Alzheimer's Disease (NILEAD)

Alzheimer Disease
Shenzhen Second People's Hospital
Dongguan People's Hospital; Zhongshan People's Hospital, Guangdong, China; The... and other collaborators

Recruiting

Nilotinib for First-line Newly Diagnosed CML-CP Patients

Chronic Myeloid Leukemia, Chronic Phase | Nilotinib

China
Andrew J. Wagner, MD, PhD
Massachusetts General Hospital; Novartis; Brigham and Women's Hospital

Active, not recruiting

Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor

Tenosynovial Giant Cell Tumor | Pigmented Villonodular Synovitis | Diffuse-type Giant Cell Tumor

United States
Novartis Pharmaceuticals

No longer available

MAP to Provide Access to Nilotinib, for Patients With HES

Hypereosinophilic Syndrome (HES)
AB Science

Completed

Masitinib in Locally Advanced/Metastatic Gastro-intestinal Stromal Tumour (GIST)

Gastro-intestinal Stromal Tumours

France
Promius Pharma, LLC

Terminated

Safety and Efficacy of NAB001 in the Treatment of Mild to Moderate Onychomycosis of the Toenails

Onychomycosis

United States
Novartis Pharmaceuticals

No longer available

MAP to Provide Access to Nilotinib, for Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia (ALL)
Novartis Pharmaceuticals

Completed

Bioavailability Study Comparing Two New Nilotinib Tablet Formulations to an Established Nilotinib Capsule Formulation in Healthy Volunteers

Healthy
Sheba Medical Center

Completed

Nilotinib Pre and Post Allogeneic Stem Cell Transplantation

Stem Cell Transplantation | Acute Lymphoblastic Leukemia | Chronic Myeloid Leukemia

Israel
Samsung Medical Center

Completed

Study of Nilotinib in Metastatic Melanoma With KIT Aberrations

Metastatic Melanoma With KIT Aberration

Korea, Republic of
University of Florida
Cord for Life, Inc.

Recruiting

Open Label Dose Ranging Study Assessing the Safety of Cord Blood Product in Sacroiliac Joint Syndrome (SIJ) (SIJ)

Pain, Back | Sacroiliac; Backache

United States
Amicus Therapeutics

Approved for marketing

Physician Initiated Expanded Access Request for Migalastat in Individual Patients With Fabry Disease

Fabry Disease

United States, Australia
University Health Network, Toronto
Novartis

Terminated

A Study of Nilotinib in Growing Vestibular Schwannomas

Growing Vestibular Schwannomas

Canada
Novartis Pharmaceuticals

Completed

CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib (MACS1428)

Chronic Myelogenous Leukemia in Chronic Phase

United States
Assistance Publique - Hôpitaux de Paris

Unknown

Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas. (NILOMEL)

Stage IV Melanoma | Stage III Melanoma | Amplification | Malignant Skin Melanoma T0

France
Promius Pharma, LLC

Terminated

Safety & Efficacy of NAB001 in the Treatment of Mild to Moderate Onychomycosis of the Toenails

Onychomycosis

United States, Dominican Republic
Seoul St. Mary's Hospital
Novartis

Unknown

Prospective Investigation of Dynamics of ABL Mutations in Imatinib Failed CML Patients Treated With Nilotinib (AMICAN)

Chronic Myeloid Leukemia

Korea, Republic of
Allakos Inc.

Completed

Study to Evaluate Multiple Doses in Patients With Nasal Polyposis

Nasal Polyposis

Belgium, United States, Germany, Netherlands, Spain, United Kingdom
Accendatech USA Inc.
Avance Clinical Pty Ltd.; C3 Research Associates

Recruiting

A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme

Recurrent Glioblastoma Multiforme(GBM)

United States
Alector Inc.
AbbVie

Recruiting

A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease

Alzheimer's Disease

Australia, Spain, United States, Italy, Canada, Poland, United Kingdom, Germany
Zhejiang University

Not yet recruiting

Safety and Efficacy Clinical Study of Severe Hemophilia B Treatment With KL001

Hemophilia B Without Inhibitor
Novartis Pharmaceuticals

Completed

An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment (MACS0999)

Chronic Myelogenous Leukemia

United States, Canada
Jill M Kolesar
National Cancer Institute (NCI); Novartis

Recruiting

Nilotinib Plus Dabrafenib/Trametinib in Metastatic Melanoma

Metastatic Melanoma | BRAF Gene Mutation

United States
Massachusetts General Hospital

Recruiting

AT1001 for the Treatment of COVID-19 Related MIS-C

Covid19 | Multisystem Inflammatory Syndrome in Children

United States
Norgine

Completed

Safety and Tolerability of a Single Intra-anal Dose of NRL001 in Healthy Volunteers

Fecal Incontinence

Bulgaria
Novartis Pharmaceuticals

Completed

Nilotinib for Patients With Chronic Myeloid Leukemia in First Line and Any Subsequent Line (NOFRETETE)

Chronic Myeloid Leukemia

Germany
Hospital for Special Surgery, New York
Novartis Pharmaceuticals; Rudolph Rupert Scleroderma Program

Completed

Nilotinib in the Treatment of Systemic Sclerosis

Systemic Sclerosis

United States
Novartis Pharmaceuticals

Completed

Pharmacokinetics of Nilotinib in Subjects With Impaired Hepatic Function and Healthy Subjects With Normal Hepatic Function

Healthy

United States
ABL Bio, Inc.

Recruiting

A Study With ABL103 in Subjects With Advanced or Metastatic Solid Tumors

Advanced Solid Tumor

Korea, Republic of

3

Subscribe